PDLIM1 and pancreatic neoplasm: However, increasing evidence recently demonstrates that PDLIM1 is dysregulated in a variety of tumors, such as colorectal cancer (CRC) [11], hepatocellular carcinoma (HCC) [12], breast cancer [13], pancreatic cancer [14], glioma [15, 16] and chronic myelogenous leukaemia (CML) [17].